Full Press Release Details
SAN RAFAEL, Calif. , June 16, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that the company will present data in a late breaking abstract session at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress being held July 8-13, 2017 in Berlin, Germany . The presentation will report interim results from a Phase 1/2 study of BMN 270, an AAV5-FVIII Gene transfer in severe hemophilia.
"We feel privileged to be presenting the only human data in gene therapy for hemophilia A at ISTH," said Hank Fuchs , M.D., President Worldwide Research and Development at BioMarin. "We are committed to further our ongoing clinical program with BMN 270, which has the potential to change the course of hemophilia A treatment, the most common form of the disease, and look forward to sharing our latest findings."
ISTH is a global not-for-profit membership organization advancing the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders. The congress hosts the world's leading experts on thrombosis, hemostasis and vascular biology, presenting the most recent advances to improve patient care.
Oral Presentation – Late Breaking Abstract Session
| Title | Authors |
| Interim Results from a Phase 1/2 AAV5-FVIII Gene Transfer in Patients with Severe Hemophilia A Presentation: July 11 at 9:30-9:38 AM CEST | J. Pasi, S. Rangarajan, L. Walsh, W. Lester, D. Perry, B. Madan, H. Yu, G.F. Pierce, W.Y. Wong |
Conference Call to be held Tuesday, July 11th at 2:30pm CEST / 8:30am ET
Interested parties may access a live webcast of the conference call via the investor section of the BioMarin website, www.biomarin.com . The Late Breaker slide presentation will be available to download in advance of the call. A replay of the call will be archived on the site for one week following the call.
U.S. / Canada Dial-in Number: (866) 502-9859 International Dial-in Number: (574) 990-1362 Conference ID: 41581309
Replay Dial-in Number: (855) 859-2056 Replay International Dial-in Number: (404) 537-3406 Conference ID: 41581309
About Hemophilia A
Hemophilia A is a genetic disease caused by the deficiency of clotting factor VIII. It is the most common type of hemophilia and occurs much more frequently in males; incidence is estimated at 1 in 4,000-5,000 male births. People born with hemophilia produce little or no clotting factors. The two main types of hemophilia are A and B. People with hemophilia A are missing or have low levels of clotting factor VIII.
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The Company's portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.BioMarin.com .
Forward Looking Statement
BioMarin ® is a registered trademark of BioMarin Pharmaceutical Inc.
| Contact: | |
| Investors: | Media: |
| Traci McCarty | Debra Charlesworth |
| BioMarin Pharmaceutical Inc. | BioMarin Pharmaceutical Inc. |
| (415) 455-7558 | (415) 455-7451 |
SOURCE BioMarin Pharmaceutical Inc.